Latest Content
-
The New Pragmatism: Clinical Trials, Investment and Regulations Post-COVID-19
Once the COVID-19 pandemic passes or is contained, the world will look and work very differently. The biopharmaceutical industry is no exception. In this podcast, Peyton Howell, Parexel’s Chief...
-
We need faster endpoints for targeted cancer drugs, and there is one
As a former regulator, Jorge shares his perspectives for the need of more faster endpoints to measure how targeted cancer drugs can benefit patients. He believes it can be created by combining two...
-
Six top tips to prepare for the new EU Clinical Trial Regulation
-
See Parexel's latest COVID-19 expert content
View all -
The impact of COVID-19 on clinical trials in rare disease and oncology
-
Five competencies for operational excellence in cell and gene therapy clinical trials
-
Three ways to improve your chances that insurers will pay for a new CGT
When developing cell and gene therapies (CGTs), drug companies face significant hurdles. One of which is getting insurance companies to pay for these treatments that can potentially cure patients...
-
How market exclusivities can affect your development program
-
3 ways to reap the benefits of adaptive-trials
-
2:08
Parexel on the pulse
Parexel regulatory expert, Mark Birse, gives an update on BREXIT.
-
Drug Development for Rare Disease and Oncology During the COVID-19 Pandemic
-
The Evolving Cell and Gene Therapy (CGT) Sector in China
-
Virtual meetings are easy, right?
Recommendations for navigating the "new normal" and how to prepare for the future.
-
1:49
Parexel on the Pulse
Paul Bridges on the EU Clinical Trial Regulation (CTR)
-
Five points to remember if FDA issues a Form 483
-
Hong Kong Exchange: Nurturing China’s Biotech Valley
About the Authors Daniel Huang is an Analyst based in the Hong Kong...
-
Crafting a genomics strategy early is key for successful oncology drug development
-
eBook: Biopharma in the COVID-19 World
-
NMPA Guidance on the Management of Clinical Trials during the COVID-19 from July 2020
Conducting clinical trials during the COVID-19 pandemic has produced many challenges globally. The initiation, conduct, implementation and completion of a trial during this time requires special...
-
Top 10 Myths About Working with the FDA for an Oncology Drug Approval
Among biotech companies, a primary concern is how to establish a clinical strategy for scientific and commercial success at the earliest stage. In that respect, regulatory considerations figure...
-
GxP On-Site Inspections are Restarting: Preparing for inspections under the “new normal”
As global regulatory agencies are preparing to return to on-site inspections1, industry needs to be ready. With the continued threat of COVID-19, the way inspections will be performed and hosted...
-
Loading More...